


Patisiran, inotersen aid hereditary transthyretin amyloidosis

July 6 2018



(HealthDay)—For patients with hereditary transthyretin amyloidosis

with polyneuropathy, an investigational RNA interference therapeutic agent (patisiran) and a 2'-*O*-methoxyethyl-modified antisense oligonucleotide (inotersen), which inhibits hepatic production of transthyretin, improve clinical manifestations of disease, according to two studies published in the July 5 issue of the *New England Journal of Medicine*.

David Adams, M.D., Ph.D., from the Université Paris-Sud, and colleagues conducted a phase 3 trial involving patients with hereditary transthyretin amyloidosis with polyneuropathy receiving either patisiran (148 patients) or [placebo](#) (77 patients). The researchers found that the least-squares mean change from baseline in the modified Neuropathy Impairment Score+7 (mNIS+7) was -6.0 ± 1.7 versus 28.0 ± 2.6 in the patisiran versus the placebo group (difference, -34.0 points) at 18 months. The least-squares mean change from baseline in the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire was -6.7 ± 1.8 versus 14.4 ± 2.7 (difference, -21.1 points) at 18 months.

Merrill D. Benson, M.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a randomized trial involving adults with stage 1 or 2 hereditary transthyretin amyloidosis with polyneuropathy. Patients were randomized to inotersen (112 patients) or placebo (60 patients). The researchers found that the difference in the least-squares mean change from baseline to week 66 favored inotersen versus placebo (-19.7 points for the mNIS+7 and -11.7 points for the Norfolk QOL-DN score).

"Inotersen improved the course of neurologic disease and quality of life in [patients](#) with hereditary transthyretin amyloidosis," Bensen and colleagues write.

The Adams study was supported by Alnylam Pharmaceuticals; the Benson study was funded by Ionis Pharmaceuticals.

More information: [Abstract/Full Text - Adams \(subscription or payment may be required\)](#)
[Abstract/Full Text - Benson \(subscription or payment may be required\)](#)
[Editorial \(subscription or payment may be required\)](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: Patisiran, inotersen aid hereditary transthyretin amyloidosis (2018, July 6) retrieved 25 February 2023 from <https://medicalxpress.com/news/2018-07-patisiran-inotersen-aid-hereditary-transthyretin.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.